U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07374809) titled 'IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER' on Jan. 21.
Brief Summary: Endometrial carcinoma (EC) represents the most common gynecological malignancy in developed countries. Despite therapeutic advances, patients with advanced or recurrent disease still have a poor prognosis, with high recurrence rates and a 5-year survival of less than 20%.
Recently, four phase III studies (RUBY, NRG-GY018, AtTEnd, and DUO-E) have demonstrated that the addition of anti-PD-1/PD-L1 immunotherapy to first-line chemotherapy significantly improves progression-free survival, particularly in tumors with altered DNA repair mechanisms known as mis...